Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase - PubMed (original) (raw)
Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase
P Levy-Mintz et al. J Virol. 1996 Dec.
Erratum in
- J Virol 1998 Apr;72(4):3505-6
- J Virol 2001 Jan;75(2):1092-3
Abstract
Integration of viral DNA into a chromosome of the infected host cell is required for efficient replication of a retroviral genome, and this reaction is mediated by the virus-encoded enzyme integrase (IN). As IN plays a pivotal role in establishing infection during the early stages of the retroviral life cycle, it is an attractive target for therapeutic intervention. However, the lack of effective antiviral drug therapy against this enzyme has led to the testing of other novel approaches towards its inhibition. In these studies, a panel of anti-human immunodeficiency virus type 1 (anti-HIV-1) IN hybridomas has been used in the construction of single-chain variable antibody fragments (SFvs). The monoclonal antibodies produced by these hybridomas, and derived SFvs, bind to different domains within IN. We now demonstrate that intracellular expression of SFvs which bind to IN catalytic and carboxy-terminal domains results in resistance to productive HIV-1 infection. This inhibition of HIV-1 replication is observed with SFvs localized in either the cytoplasmic or nuclear compartment of the cell. The expression of anti-IN SFvs in human T-lymphocytic cells and peripheral blood mononuclear cells appears to specifically neutralize IN activity prior to integration and, thus, has an effect on the integration process itself. These data support our previous studies with an anti-HIV-1 reverse transcriptase SFv and demonstrate further that intracellularly expressed SFvs can gain access to viral proteins of the HIV-1 preintegration complex. This panel of anti-HIV-1 IN SFvs also provides the tools with which to dissect the molecular mechanism(s) directly involved in integration within HIV-1-infected cells.
Comment in
- Findings of scientific misconduct.
[No authors listed] [No authors listed] NIH Guide Grants Contracts. 2000 Jun 27:OD-00-043. NIH Guide Grants Contracts. 2000. PMID: 12458562 Free PMC article. No abstract available.
Similar articles
- Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition.
Wu Y, Duan L, Zhu M, Hu B, Kubota S, Bagasra O, Pomerantz RJ. Wu Y, et al. J Virol. 1996 May;70(5):3290-7. doi: 10.1128/JVI.70.5.3290-3297.1996. J Virol. 1996. PMID: 8627813 Free PMC article. - Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle.
Shaheen F, Duan L, Zhu M, Bagasra O, Pomerantz RJ. Shaheen F, et al. J Virol. 1996 Jun;70(6):3392-400. doi: 10.1128/JVI.70.6.3392-3400.1996. J Virol. 1996. PMID: 8648670 Free PMC article. - Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase.
Kitamura Y, Ishikawa T, Okui N, Kobayashi N, Kanda T, Shimada T, Miyake K, Yoshiike K. Kitamura Y, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Feb 1;20(2):105-14. doi: 10.1097/00042560-199902010-00001. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 10048896 - Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS.
Marasco WA, LaVecchio J, Winkler A. Marasco WA, et al. J Immunol Methods. 1999 Dec 10;231(1-2):223-38. doi: 10.1016/s0022-1759(99)00159-3. J Immunol Methods. 1999. PMID: 10648940 Review. - Human antibody variable region gene usage in HIV-1 infection.
Wisnewski A, Cavacini L, Posner M. Wisnewski A, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):31-8. doi: 10.1097/00042560-199601010-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8528730 Review.
Cited by
- Capsid-Targeted Viral Inactivation: A Novel Tactic for Inhibiting Replication in Viral Infections.
Zhang X, Jia R, Zhou J, Wang M, Yin Z, Cheng A. Zhang X, et al. Viruses. 2016 Sep 21;8(9):258. doi: 10.3390/v8090258. Viruses. 2016. PMID: 27657114 Free PMC article. Review. - Architecture of a full-length retroviral integrase monomer and dimer, revealed by small angle X-ray scattering and chemical cross-linking.
Bojja RS, Andrake MD, Weigand S, Merkel G, Yarychkivska O, Henderson A, Kummerling M, Skalka AM. Bojja RS, et al. J Biol Chem. 2011 May 13;286(19):17047-59. doi: 10.1074/jbc.M110.212571. Epub 2011 Mar 15. J Biol Chem. 2011. PMID: 21454648 Free PMC article. - Engineering T Cells to Functionally Cure HIV-1 Infection.
Leibman RS, Riley JL. Leibman RS, et al. Mol Ther. 2015 Jul;23(7):1149-1159. doi: 10.1038/mt.2015.70. Epub 2015 Apr 21. Mol Ther. 2015. PMID: 25896251 Free PMC article. Review. - Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes.
Nermut MV, Fassati A. Nermut MV, et al. J Virol. 2003 Aug;77(15):8196-206. doi: 10.1128/jvi.77.15.8196-8206.2003. J Virol. 2003. PMID: 12857888 Free PMC article. - Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.
Sakkhachornphop S, Barbas CF 3rd, Keawvichit R, Wongworapat K, Tayapiwatana C. Sakkhachornphop S, et al. Hum Gene Ther. 2012 Sep;23(9):932-42. doi: 10.1089/hum.2011.124. Epub 2012 May 8. Hum Gene Ther. 2012. PMID: 22429108 Free PMC article.
References
- J Virol. 1996 Feb;70(2):1282-7 - PubMed
- J Virol. 1996 May;70(5):3290-7 - PubMed
- J Biol Chem. 1996 Mar 29;271(13):7712-8 - PubMed
- J Virol. 1996 Jun;70(6):3392-400 - PubMed
- Hum Gene Ther. 1995 Dec;6(12):1561-73 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials